A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer
- Conditions
- Ovarian CancerBiomarker
- Interventions
- Genetic: Sequencing of DNA, RNA, and Proteins
- Registration Number
- NCT06483425
- Lead Sponsor
- Tongji Hospital
- Brief Summary
This clinical trial aims to investigate the role of biomarkers in guiding precision treatment for ovarian cancer. The study will explore the effectiveness of personalized treatment strategies based on specific biomarkers identified in ovarian cancer patients. By analyzing the correlation between biomarker profiles and treatment outcomes, the trial seeks to optimize treatment decisions and improve overall survival rates in ovarian cancer patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- Female
- Target Recruitment
- 2000
- Patients diagnosed with ovarian cancer.
- Willingness to undergo biomarker testing.
- Ability to provide informed consent for participation in the study.
- Inability to comply with study requirements or follow-up visits.
- Previous participation in a conflicting clinical trial.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Ovarian cancer pateitns Sequencing of DNA, RNA, and Proteins Patients diagnosed with Ovarian cancer in Tongji Hospital, Wuhan.
- Primary Outcome Measures
Name Time Method Biomarker explorarion 5 years Blood, tumor, and other samples should be sequenced by RNA-seq, Next-Generation Sequencing, or proteomics to identify specific biomarkers associated with treatment response and prognosis in ovarian cancer.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
🇨🇳Wuhan, Hubei, China